Diagnostic Methods & Treatment Of Tiopronin †MyAssignmenthelp.com

Question: Discuss about the Diagnostic Methods And Treatment Of Tiopronin. Answer: Name Class and Structure of Tiopronitin Tiopronin contains acylatedsufhydryl and is a derivative of glycine. It has reducing and complexing properties (16). Tiopronin cleaves disulfide bonds found in cystine molecules, and then bind the sufhydryl group of the monomers of cysteine (5). These results in the formation of Tiopronin-cysteine-mixed disulfide, that is readily soluble in water (more than cystine) and thus can be readily excreted. This can help to reduce cystine concentration in urine, and therefore can be used to treat formation of cystine stone (4). Biochemical Pathway (Substrates/Precursors) Cystine is the substrate for biochemical pathway for Tiopronitin and the precursor form is -Ethylxanthogenpropionylglycin, -Benzylmercaptopropionylglycin, 2-(2-benzoylsulfanylpropanoylamino) acetic acid, (2-Bromo-Propionylamino)-Acetic Acid (5). Tiopronin can affect secretary pathways of Endoplasmic Reticulum, Golgi, Lissome, and Vesicles, particularly the kidneys. In effect, it can be involved in any activity where cystine is involved (5). The principle metabolite is 2-mercaptopropionic acid (2-MPA) (6). Effects of Manipulator Cellular/ Tissue level: Tiopronin can augment the levels of intracellular cysteine by disulfide exchange reactions. An increased availability of cysteine causes an augmentation in the formation of cystathionine. Also helps to maintain low levels of intercellular cystine. Molecular basis of cystinuria is linked with the failure of the cellular transport system, caused by mutation in SLCA1 and SLC7A9 genes (8). These genes code for a heterodimer that helps to reabsorb filtered cystine from the proximal tubule of nephron. Extensive protein binding occurs in the plasma by forming disulfide bridges (7). Organism level: Reduction in the concentration cystine in urine reduces the risks of kidney stones. Tiopronin is absorbed slowly.Peak concentration is reached 3-6 hours after ingesting. It is 100% excitable via urine. Half-life is about 53 hours (8). Total renal clearance (total and unbound) at 3.3 to 13.3 L/Hr. High doses can interfere with the maintenance of pregnancy and fetus viability (19). Biochemical synthesis: N substituted glycines are substrates for peptidylglycine a-amidatingmonooxygenase. [Figure 1: Preparation from thiorphan. Source] Tiopronin is synthesized from its precursor molecules, and then the crystals are extracted. There are 4 synthesis routes for the preparation of Tiopronin. Each route starts from a of the precursor molecule, mentioned above (9). [Figure 2: Tiopronin preparation. Source: www.ebi.ac.uk] Crude Tiopronin (TPN) is thiol containing glycine derivative. It is extracted by ethyl acetate (EA) from aqueous solution, evaporated and concentrated to get TPN crystals. TPN dissolved in deionized water is extracted by EA reagent by counter current extraction (10). Co factor activity: Pyridoxine is a cofactor for alanine glycoxilate aminotransferase (AGT), which catalyses the conversion of glyoxilate to glycine, which is the parent molecule of Tiopronin (15). Deficiency of AGT causes the formation of oxalate from glyoxalate (3). Half Life: Tiopronin has a long half-life of 53 hours. However, in the unbound state the drug fraction of Tiopronin can be eliminated from blood plasma with 1.8 hours of calculated half-life. Toxicity: Due to recycling process of Tiopronin, the overall level of toxicity is increased in bloodLong term carcinogenicity and mutagenicity studies on the effect of Tiopronin have not been done. Experimental animal studies have shown an interference with the processes that maintain pregnancy and viability of fetus (12). The possibility of teratogenicity has not been ruled out; due to the usage of Tiopronin, since d-penicillamine (a drug that has similar mechanism) is has been related to teratogenicity (20). Tiopronin is not recommended for breastfeeding mothers, and its safety in usage for children below 9 years has not been established (11). Research The recent research work has highlighted upon few of the important characteristics that is related to the metabolism of alcohol that is influenced by the activity of Tiopronin. From experimental studies, it is clear that effects of Tiopronin have little or no significance in the alcohol level of blood (13). This is due to the fact that all the changes that are done in the level of alcohol can be altered due to the fact that the changes are reversible. The biochemical reactions that occur in the blood alcohol level are reversible (2). Diagnosis Most of the diseases related to the activity of Tioproninare caused due to alter in the rate of metabolic reactions. It has been seen that oral health disease is caused due to the effects of Tiopronin. Cystinuria is also one of the names of the disease that is caused due to the effects of Tiopronin (14). The cysteine stone is one of the genetic disorders that is caused due to the activity of Tiopronin. This one of the major genetic autosomal disorders, which can be prevented through possible medication that includes through penicillamine (15). Treatment The treatment can for the disorder for Tiopronin can be treated with the gene therapy. The dosage of the medication depends upon the type of therapy. The medication is followed by plenty of water as an important part of the diet. The dosage of the medication depends upon the body weight of the patient (1). The side effects that are associated with the disease includes that of skin complications and other forms of hypersensitivity reactions. The quality of the life of the patient worsen due to the adverse side effects associated with the medication (17). Policy The legal policy related to that of treatment of Tiopronin is related with that of the ethical concerns associated with that of gene therapy. The legal procedures also follows the policy that are associated with that of the drugs (18). The selling of the drugs related to that of Tiopronin has be done under particular trade license of drug and chemical selling. It is also essential for the drug manufacturer to provide detail and relevant information about the composition of the drugs. The manufactures also have the legal duty to make necessary precautions for all forms of adverse situations that are associated with the use of the drugs (5) References Koene S, Smeitink J. Metabolic manipulators: a well-founded strategy to combat mitochondrial dysfunction. Journal of inherited metabolic disease. 2011 Apr 1;34(2):315-25. ncbi.nlm.nih.gov. tiopronin [Internet]. Pubchem.ncbi.nlm.nih.gov. 2017 [cited 13 October 2017]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/tiopronin#section=Top Uda J, Wakamatsu H, Yamagami N, inventors; Ajinomoto Kk, assignee. Method of producing n acyl alpha amino acids. United States patent US 3,766,266. 1973 Oct 16. Claes DJ, Jackson E. Cystinuria: mechanisms and management. Pediatric Nephrology. 2012 Nov 1;27(11):2031-8. Lopez-Tobar E, Herna?ndez B, Ghomi M, Sanchez-Cortes S. Stability of the disulfide bond in cystine adsorbed on silver and gold nanoparticles as evidenced by SERS data. The Journal of Physical Chemistry 2013 Jan 10;117(3):1531-7. Fattah H, Hambaroush Y, Goldfarb DS. Cystine nephrolithiasis. Translational andrology and urology. 2014 Sep 1;3(3):228. Saravakos P, Kokkinou V, Giannatos E. Cystinuria: current diagnosis and management. Urology. 2014 Apr 30;83(4):693-9. Sela M, White Jr FH, Anfinsen CB. Reductive cleavage of disulfide bridges in ribonuclease. Science. 1957 Apr 12;125(3250):691-2. Meister A. Biochemistry of the amino acids. Elsevier; 2012 Dec 2. Tang Z, He Z, Li H, Guo D, Zhao Z. Process Intensification in Tiopronin Extraction. International Journal of Chemical Engineering and Applications. 2016 Dec 1;7(6):433. Huo S, Shi H, Liu D, Shen S, Zhang J, Song C, Shi T. Kinetics and mechanism of reactions of the drug tiopronin with platinum (IV) complexes. Journal of inorganic biochemistr 2013 Aug 31;125:9-15. Huo S, Jin S, Zheng K, He S, Wang D, Liang X. Preparation and characterization of doxorubicin functionalized tiopronin-capped gold nanorods for cancer therapy. Chin Sci Bull. 2013 Aug 23;58:4072-6. ac.uk E. ChEMBL [Internet]. Ebi.ac.uk. 2017 [cited 13 October 2017]. Available from: https://www.ebi.ac.uk/chembl/bioactivity/results/1/cmpd_chemblid/asc/tab/display